PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief

HERZLIYA, Israel – March 17, 2021 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end business update.  The Company also reported it has filed its annual report on Form 20-F. Significant events and achievements during the fourth quarter […]

PainReform Announces $6.0 Million Private Placement

HERZLIYA, Israel – March 8, 2021 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics,today announced that it has entered into securities purchase agreements with certain institutional investors to raise approximately $6.0 million through the private placement of 1,304,346 ordinary shares and […]

PainReform to Present at the H.C. Wainwright Bioconnect 2021 Conference

HERZLIYA, Israel – January 6, 2021 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021. A webcast of PainReform’s presentation will be […]

PainReform Announces Appointment of Lotus Clinical Research as CRO for Phase 3 Clinical Trial of PRF-110

Reports steady progress towards start of Phase 3 trial HERZLIYA, Israel – January 4, 2021 – PainReform Ltd. (NasdaqCM: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established pain drugs, today announced the appointment of Lotus Clinical Research (“LCR”) as its clinical research organization (“CRO”) to conduct the Company’s […]

PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations

HERZLIYA, Israel – January 6, 2021 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the appointment of Rita Keynan as Vice President of Pharmaceutical Operations. Mrs. Keynan brings over 25 years of managerial experience in the pharmaceutical industry. Mrs. Keynan has been […]

PainReform Appoints Senior Pharmaceutical Executive and Finance Veteran Ilan Hadar as Chief Executive Officer

HERZLIYA, ISRAEL / ACCESSWIRE / November 23, 2020 / PainReform Ltd. (NASDAQ:PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the appointment of Ilan Hadar as Chief Executive Officer. Mr. Hadar brings over 20 years of multinational managerial and corporate experience with pharmaceutical and high-tech companies. Mr. Hadar has been instrumental in building companies from start-ups […]

PainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors

HERZLIYA, ISRAEL / ACCESSWIRE / November 5, 2020 / PainReform Ltd. (NASDAQ:PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, welcomes Augustine Lawlor as a member of the Company’s Board of Directors following its recent initial public offering. Mr. Lawlor has served as Chief Operating Officer of Leap Therapeutics, Inc., an oncology company, since January 2016 and […]

PainReform Highlights Surgical Advantages of PRF-110

Studies demonstrate unique benefits of PRF-100 beyond analgesic activity PRF-110 addresses potential concerns in the local administration of anesthetic related to wound healing and suture integrity that are commonly involved in surgical procedures HERZLIYA, ISRAEL / ACCESSWIRE / October 19, 2020 / PainReform Ltd. (NASDAQCM:PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established […]

PainReform Commences Preparations for Pivotal Phase 3 Clinical Trials

HERZLIYA, ISRAEL / ACCESSWIRE / September 29, 2020 / PainReform Ltd. (NASDAQ:PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that following the closing of its initial public offering, it has commenced preparations for the launch of its pivotal Phase 3 clinical trials of PRF-110 for the treatment of post-operative […]